Literature DB >> 9256846

Adverse drug events in high risk older outpatients.

J T Hanlon1, K E Schmader, M J Koronkowski, M Weinberger, P B Landsman, G P Samsa, I K Lewis.   

Abstract

OBJECTIVE: To describe the prevalence, types, and consequences of adverse drug events (ADEs) in older outpatients with polypharmacy.
DESIGN: A cohort study.
SETTING: General Medicine Clinic at the Durham Veterans Affairs Medical Center. PATIENTS: A total of 167 high risk (taking > or = 5 scheduled medications) ambulatory older veterans who participated in a year long health service intervention trial. MEASUREMENTS: Potential ADEs were identified by asking patients during closeout interviews whether, in the past year, they had experienced any side effects, unwanted reactions, or other problems from any medication. All reported medications and corresponding adverse experiences were assessed for plausibility by a research clinical pharmacist using two standard pharmacological textbooks and categorized by predictability, therapeutic class, and organ system.
RESULTS: Eighty self-reported ADEs involving 72 medications taken by 58 (35%) of 167 patients were textbook confirmed. Seventy-six of 80 (95%) ADEs were classified as Type A (predictable) reactions. Cardiovascular (33.3%) and central nervous system (27.8%) medication classes were most commonly implicated. Gastrointestinal (30%) and central nervous system (28.8%) ADE symptoms were common. Sixty-three percent of patients with ADEs required physician contacts, 10% emergency room visits, and 11% hospitalization. Twenty percent of medications implicated with ADEs required dosage adjustments, and 48% of ADE-related medications were discontinued. No significant differences (P > .05) were observed when ADE reporters (n = 58) and nonreporters (n = 109) were compared.
CONCLUSION: Predictable ADEs are common in high risk older outpatients, resulting in considerable medication modification and substantial healthcare utilization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256846     DOI: 10.1111/j.1532-5415.1997.tb02964.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  89 in total

Review 1.  Assessing medication appropriateness in the elderly: a review of available measures.

Authors:  P S Shelton; M A Fritsch; M A Scott
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  Adverse drug reactions in a population of hospitalized very elderly patients.

Authors:  Balamurugan Tangiisuran; J Graham Davies; Juliet E Wright; Chakravarthi Rajkumar
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

Review 3.  [Polypharmacy and falls in the Elderly].

Authors:  Ulrike Sommeregger; Bernhard Iglseder; Birgit Böhmdorfer; Ursula Benvenuti-Falger; Peter Dovjak; Monika Lechleitner; Ronald Otto; Regina E Roller; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2010-06

4.  [Multiple drug therapy - a challenge for an aging society].

Authors:  Markus Gosch; Regina E Roller
Journal:  Wien Med Wochenschr       Date:  2010-06

Review 5.  Polypharmacy in older adults with cancer.

Authors:  Ronald J Maggiore; Cary P Gross; Arti Hurria
Journal:  Oncologist       Date:  2010-04-24

6.  Detecting medication errors in the New Zealand pharmacovigilance database: a retrospective analysis.

Authors:  Desireé L Kunac; Michael V Tatley
Journal:  Drug Saf       Date:  2011-01-01       Impact factor: 5.606

Review 7.  Underprescription of beneficial medicines in older people: causes, consequences and prevention.

Authors:  Antonio Cherubini; Andrea Corsonello; Fabrizia Lattanzio
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

Review 8.  Routine deprescribing of chronic medications to combat polypharmacy.

Authors:  Doron Garfinkel; Birkan Ilhan; Gulistan Bahat
Journal:  Ther Adv Drug Saf       Date:  2015-12

Review 9.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

10.  Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?

Authors:  Adam Todd; Steve Williamson; Andy Husband; Wasim Baqir; Mairead Mahony
Journal:  Int J Clin Pharm       Date:  2012-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.